Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a clinical-stage biotechnology company with a strong candidate, Neflamapimod, for treating neurological disorders such as dementia with Lewy bodies (DLB). The company's recent MRI data showed potential for reducing basal forebrain atrophy, a structural marker associated with cognitive decline in DLB, and improving functional connectivity. This, coupled with the company's alignment with global regulatory authorities on the Phase 3 pathway and finalized trial design, make CervoMed a promising and leading contender in the race for a first-in-class treatment for DLB. Additionally, the company's risk factors, such as clinical/regulatory, partnership and financial, and market share risks, have been adequately addressed, providing a positive outlook for potential investors.

Bears say

CervoMed is facing numerous risks, such as the possibility of not being able to initiate its Phase 3 trial of neflamapimod in DLB in a timely manner, and the potential failure to generate positive data or secure regulatory approval for the drug. Additionally, there is a risk of slower market uptake and potential dilution in the near to medium-term. Furthermore, while the increase in basal forebrain volume and connectivity shown in recent studies is promising, there is still uncertainty around the effectiveness of Neflamapimod in treating age-related neurologic disorders.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.